SCHEMBL22018907

SCHEMBL22018907

CCOC(=O)c1c(NC(=O)C(F)(F)F)nn2ccc(=O)[nH]c12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAT P00750 9/20 0.44
TRPM8 Q7Z2W7 1/20 0.43
ADORA3 P0DMS8 1/20 0.37
ALDH1A1 P00352 2/20 0.36
SPR P35270 1/20 0.35
MAPT P10636 3/20 0.34
PDK1 Q15118 1/20 0.34
PDK2 Q15119 1/20 0.34
PDK3 Q15120 1/20 0.34
PDK4 Q16654 1/20 0.34
NPC1 O15118 2/20 0.34
LMNA P02545 2/20 0.34
RAB9A P51151 2/20 0.34
ATM Q13315 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
GLA P06280 1/20 0.34
GAA P10253 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14881615 0.80 PLAT (0.53) PLATADORA3ALDH1A1MAPTNPC1
SCHEMBL23013790 0.78 PLAT (0.43) PLATADORA3ALDH1A1SPRMAPT
SCHEMBL15307002 0.78 KMT2A (0.46) PLATADORA3ALDH1A1MAPTNPC1
SCHEMBL20694710 0.76 TRPM8 (0.45) TRPM8ALDH1A1MAPTPDK1PDK2
SCHEMBL24833959 0.75 PLAT (0.41) PLATADORA3ALDH1A1MAPTNPC1
SCHEMBL404918 0.68 PLAT (0.53) PLATALDH1A1MAPTNPC1LMNA
SCHEMBL28516116 0.68 ALDH1A1 (0.49) ALDH1A1MAPTNPC1LMNARAB9A
SCHEMBL14881835 0.65 MAPT (0.42) PLATADORA3ALDH1A1SPRMAPT
SCHEMBL24274526 0.65 ADORA3 (0.46) PLATADORA3ALDH1A1SPRMAPT
SCHEMBL17820828 0.65 PLAT (0.36) PLATNPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3658148-B1 MACROCYCLIC COMPOUNDS AND USES THEREOF TURNING POINT THERAPEUTICS INC (US) 2024-07-10 EP disclosed
US-11155563-B2 Macrocyclic compounds and uses thereof Turning Point Therapeutics, Inc. (US) 2021-10-26 US disclosed
US-20210214373-A1 MACROCYCLIC COMPOUNDS AND USES THEREOF Turning Point Therapeutics, Inc. 2021-07-15 US disclosed
US-20200157119-A1 MACROCYCLIC COMPOUNDS AND USES THEREOF Turning Point Therapeutics, Inc. 2020-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11155563-B2 Macrocyclic compounds and uses thereof CSF3R, CSF1R, FLT3 PLAT 2612/4885TRPM8 2529/4885ADORA3 2244/4885
US-20200157119-A1 MACROCYCLIC COMPOUNDS AND USES THEREOF CSF3R, CSF1R, FLT3 PLAT 2612/4885TRPM8 2529/4885ADORA3 2244/4885
US-20210214373-A1 MACROCYCLIC COMPOUNDS AND USES THEREOF CSF3R, CSF1R, FLT3 PLAT 2612/4885TRPM8 2529/4885ADORA3 2244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.